Recruiting
Phase 3

Olanzapine

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06200181

Conditions

Misuse, Opioid

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Olanzapine

Olanzapine

Placebo

Study Details

Brief summary:

To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.

Conditions

Misuse, Opioid

Study ID

NCT06200181

Start date

Apr 2, 2024

Status verified date

May, 2026

Completion date

Nov 1, 2026

Anticipated

Primary completion date

Nov 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age 18 years or older
2. Diagnosis of cancer pain
3. Receiving long-term opioid therapy (≥ 7 days)32
4. Active use of opioids within the past 7 days
5. Opioid misuse behavior (COMM score ≥ 9/68)
6. Seen by a Supportive Care Clinic or Pain Clinic clinician
7. ECOG performance status ≥ 2/4
8. Ability to communicate in English
9. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Contraindications to, or allergic to, olanzapine
2. Current use of any antipsychotic medication (e.g. quetiapine, haloperidol, risperidone, etc.)
3. History of OUD or other substance use disorders, except marijuana
4. History of formal psychiatric diagnoses (e.g. bipolar disorder, schizophrenia, major depressive disorder, or anorexia nervosa)
5. Hepatic insufficiency (defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the highest normal value, or total bilirubin >1.5 times the highest normal value) within the past month
6. History of uncontrolled Diabetes Mellitus or hyperglycemia (fasting ≥ 200 mg/dL) within the past month
7. History of seizure disorder or neuroleptic malignant syndrome
8. History of cardiac disease (e.g. coronary artery disease, congestive heart failure)
9. (Females only) Known pregnancy, as communicated to study personnel by clinicians; females of childbearing potential will receive advice to use methods of contraception per usual care.

Study Design

Enrollment

87 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Arm 1

Participants will take a lower dose of olanzapine every day for Days 1-7 and then a higher dose every day for the next 3 weeks

experimental: Arm 2

Participants will take the lower dose of olanzapine every day for 4 weeks.

placebo comparator: Arm 3

Participants will take a placebo every day for 4 weeks.

Interventions

Olanzapine

Given by PO

Olanzapine

Given by PO

Placebo

Given by PO

Primary outcome measure

  • Safety and adverse events (AEs [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts and Locations

Central contacts

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Joseph Arthur, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Jun 1, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-06-01.